{"pmid":32490889,"title":"Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.","text":["Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results.","Mem Inst Oswaldo Cruz","Biembengut, Isis Venturi","de Souza, Tatiana de Arruda Campos Brasil","32490889"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results."],"journal":"Mem Inst Oswaldo Cruz","authors":["Biembengut, Isis Venturi","de Souza, Tatiana de Arruda Campos Brasil"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490889","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1590/0074-02760200179","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169272819713,"score":9.490897,"similar":[{"pmid":32485894,"title":"In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.","text":["In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.","The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Since the development of novel drugs is a long-lasting process, researchers look for effective substances among drugs already approved or developed for other purposes. The 3D structure of the SARS-CoV-2 main protease was compared with the 3D structures of seven proteases, which are drug targets, and docking analysis to the SARS-CoV-2 protease structure of thirty four approved and on-trial protease inhibitors was performed. Increased 3D structural similarity between the SARS-CoV-2 main protease, the HCV protease and alpha-thrombin was found. According to docking analysis the most promising results were found for HCV protease, DPP-4, alpha-thrombin and coagulation Factor Xa known inhibitors, with several of them exhibiting estimated free binding energy lower than -8.00 kcal/mol and better prediction results than reference compounds. Since some of the compounds are well-tolerated drugs, the promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with anti-viral action may be more useful for infected patients with diabetes, while anti-coagulant treatment is proposed in severe SARS-CoV-2 induced pneumonia.","Molecules","Eleftheriou, Phaedra","Amanatidou, Dionysia","Petrou, Anthi","Geronikaki, Athina","32485894"],"abstract":["The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Since the development of novel drugs is a long-lasting process, researchers look for effective substances among drugs already approved or developed for other purposes. The 3D structure of the SARS-CoV-2 main protease was compared with the 3D structures of seven proteases, which are drug targets, and docking analysis to the SARS-CoV-2 protease structure of thirty four approved and on-trial protease inhibitors was performed. Increased 3D structural similarity between the SARS-CoV-2 main protease, the HCV protease and alpha-thrombin was found. According to docking analysis the most promising results were found for HCV protease, DPP-4, alpha-thrombin and coagulation Factor Xa known inhibitors, with several of them exhibiting estimated free binding energy lower than -8.00 kcal/mol and better prediction results than reference compounds. Since some of the compounds are well-tolerated drugs, the promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with anti-viral action may be more useful for infected patients with diabetes, while anti-coagulant treatment is proposed in severe SARS-CoV-2 induced pneumonia."],"journal":"Molecules","authors":["Eleftheriou, Phaedra","Amanatidou, Dionysia","Petrou, Anthi","Geronikaki, Athina"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32485894","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/molecules25112529","keywords":["dpp-4 inhibitors","hcv protease inhibitors","sars-cov-2","a-thrombin inhibitors","coronavirus","docking","protease inhibitors"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169452126208,"score":289.2774},{"pmid":32329419,"title":"Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.","text":["Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.","SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Enmozhi, Sukanth Kumar","Raja, Kavitha","Sebastine, Irudhayasamy","Joseph, Jerrine","32329419"],"abstract":["SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Enmozhi, Sukanth Kumar","Raja, Kavitha","Sebastine, Irudhayasamy","Joseph, Jerrine"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329419","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1760136","keywords":["andrographolide","sars-cov-2","swiss-bioinformatics","in silico studies","plant compound"],"locations":["Andrographis"],"e_drugs":["remdesivir","Chloroquine","Hydroxychloroquine","andrographolide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494594973696,"score":257.93222},{"pmid":32441299,"title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19.","text":["Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19.","Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of SARS-CoV-2. Here, we utilized a structure-based drug design approach to find possible drug candidates from the existing pool of FDA-approved drugs and checked their effectiveness against the SARS-CoV-2. We performed virtual screening of the FDA approved drugs against the main protease (Mpro) of SARS-CoV-2, an essential protein, and a potential drug target. Using well-defined computational methods, we identified Glecaprevir and Maraviroc as the best inhibitors CoV-2 Mpro. Both drugs bind to the substrate-binding pocket of SARS-CoV-2 Mpro and form a significant number of non-covalent interactions. Glecaprevir and Maraviroc bind to the conserved substrate-binding pocket of SARS-CoV-2 Mpro. This work provides sufficient evidence for the use of Glecaprevir and Maraviroc for the therapeutic management of COVID-19.","Biosci Rep","Shamsi, Anas","Mohammad, Taj","Anwar, Saleha","Alajmi, Mohamed","Hussain, Afzal","Rehman, Md Tabish","Islam, Asimul","Hassan, Md Imtaiyaz","32441299"],"abstract":["Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of SARS-CoV-2. Here, we utilized a structure-based drug design approach to find possible drug candidates from the existing pool of FDA-approved drugs and checked their effectiveness against the SARS-CoV-2. We performed virtual screening of the FDA approved drugs against the main protease (Mpro) of SARS-CoV-2, an essential protein, and a potential drug target. Using well-defined computational methods, we identified Glecaprevir and Maraviroc as the best inhibitors CoV-2 Mpro. Both drugs bind to the substrate-binding pocket of SARS-CoV-2 Mpro and form a significant number of non-covalent interactions. Glecaprevir and Maraviroc bind to the conserved substrate-binding pocket of SARS-CoV-2 Mpro. This work provides sufficient evidence for the use of Glecaprevir and Maraviroc for the therapeutic management of COVID-19."],"journal":"Biosci Rep","authors":["Shamsi, Anas","Mohammad, Taj","Anwar, Saleha","Alajmi, Mohamed","Hussain, Afzal","Rehman, Md Tabish","Islam, Asimul","Hassan, Md Imtaiyaz"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441299","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1042/BSR20201256","keywords":["coronavirus disease 2019","fda approved drugs","sars-cov-2","drug repurposing","molecular docking","virtual screening"],"locations":["Maraviroc","Maraviroc","Maraviroc","Maraviroc"],"e_drugs":["Maraviroc","ABT-493"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119461646336,"score":250.43187},{"pmid":32476576,"title":"Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.","text":["Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.","Coronaviruses are contagious pathogens primarily responsible for respiratory and intestinal infections. Research efforts to develop antiviral agents against coronavirus demonstrated the main protease (Mpro) protein may represent effective drug target. X-ray crystallographic structure of the SARS-CoV2 Mpro protein demonstrated the significance of Glu166, Cys141, and His41 residues involved in protein dimerization and its catalytic function. We performed in silico screening of compounds from Curcuma longa L. (Zingiberaceae family) against Mpro protein inhibition. Employing a combination of molecular docking, scoring functions, and molecular dynamics simulations, 267 compounds were screened by docking on Mpro crystallographic structure. Docking score and interaction profile analysis exhibited strong binding on the Mpro catalytic domain with compounds C1 (1E,6E)-1,2,6,7-tetrahydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3, 5-dione) and C2 (4Z,6E)-1,5-dihydroxy-1,7-bis(4-hydroxyphenyl)hepta-4,6-dien-3-one as lead agents. Compound C1 and C2 showed minimum binding score (-9.08 and -8.07 kcal/mole) against Mpro protein in comparison to shikonin and lopinavir ( approximately -5.4 kcal/mole) a standard Mpro inhibitor. Furthermore, principal component analysis, free energy landscape and protein-ligand energy calculation studies revealed that these two compounds strongly bind to the catalytic core of the Mpro protein with higher efficacy than lopinavir, a standard antiretroviral of the protease inhibitor class. Taken together, this structure based optimization has provided lead on two natural Mpro inhibitors for further testing and development as therapeutics against human coronavirus.","J Biomol Struct Dyn","Gupta, Sanjay","Singh, Atul Kumar","Kushwaha, Prem Prakash","Prajapati, Kumari Sunita","Shuaib, Mohd","Senapati, Sabyasachi","Kumar, Shashank","32476576"],"abstract":["Coronaviruses are contagious pathogens primarily responsible for respiratory and intestinal infections. Research efforts to develop antiviral agents against coronavirus demonstrated the main protease (Mpro) protein may represent effective drug target. X-ray crystallographic structure of the SARS-CoV2 Mpro protein demonstrated the significance of Glu166, Cys141, and His41 residues involved in protein dimerization and its catalytic function. We performed in silico screening of compounds from Curcuma longa L. (Zingiberaceae family) against Mpro protein inhibition. Employing a combination of molecular docking, scoring functions, and molecular dynamics simulations, 267 compounds were screened by docking on Mpro crystallographic structure. Docking score and interaction profile analysis exhibited strong binding on the Mpro catalytic domain with compounds C1 (1E,6E)-1,2,6,7-tetrahydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3, 5-dione) and C2 (4Z,6E)-1,5-dihydroxy-1,7-bis(4-hydroxyphenyl)hepta-4,6-dien-3-one as lead agents. Compound C1 and C2 showed minimum binding score (-9.08 and -8.07 kcal/mole) against Mpro protein in comparison to shikonin and lopinavir ( approximately -5.4 kcal/mole) a standard Mpro inhibitor. Furthermore, principal component analysis, free energy landscape and protein-ligand energy calculation studies revealed that these two compounds strongly bind to the catalytic core of the Mpro protein with higher efficacy than lopinavir, a standard antiretroviral of the protease inhibitor class. Taken together, this structure based optimization has provided lead on two natural Mpro inhibitors for further testing and development as therapeutics against human coronavirus."],"journal":"J Biomol Struct Dyn","authors":["Gupta, Sanjay","Singh, Atul Kumar","Kushwaha, Prem Prakash","Prajapati, Kumari Sunita","Shuaib, Mohd","Senapati, Sabyasachi","Kumar, Shashank"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476576","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/07391102.2020.1776157","keywords":["curcuma longa","inhibitor","md simulation","main protease","sars-cov-2"],"locations":["Curcuma"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668437835197186050,"score":247.11096},{"pmid":32362243,"title":"Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.","text":["Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.","The 2019-novel coronavirus (nCoV) has caused a global health crisis by causing coronavirus disease-19 (COVID-19) pandemic in the human population. The unavailability of specific vaccines and anti-viral drug for nCoV, science demands sincere efforts in the field of drug design and discovery for COVID-19. The novel coronavirus main protease (SARS-CoV-2 Mpro) play a crucial role during the disease propagation, and hence SARS-CoV-2 Mpro represents as a drug target for the drug discovery. Herein, we have applied bioinformatics approach for screening of chemical compounds from Indian spices as potent inhibitors of SARS-CoV-2 main protease (PDBID: 6Y84). The structure files of Indian spices chemical compounds were taken from PubChem database or Zinc database and screened by molecular docking, by using AutoDock-4.2, MGLTools-1.5.6, Raccoon virtual screening tools. Top 04 hits based on their highest binding affinity were analyzed. Carnosol exhibited highest binding affinity -8.2 Kcal/mol and strong and stable interactions with the amino acid residues present on the active site of SARS-CoV-2 Mpro. Arjunglucoside-I (-7.88 Kcal/mol) and Rosmanol (-7.99 Kcal/mol) also showed a strong and stable binding affinity with favourable ADME properties. These compounds on MD simulations for 50ns shows strong hydrogen-bonding interactions with the protein active site and remains stable inside the active site. Our virtual screening results suggest that these small chemical molecules can be used as potential inhibitors against SARS-CoV-2 Mpro and may have an anti-viral effect on nCoV. However, further validation and investigation of these inhibitors against SARS-CoV-2 main protease are needed to claim their candidacy for clinical trials.","J Biomol Struct Dyn","Umesh","Kundu, Debanjan","Selvaraj, Chandrabose","Singh, Sanjeev Kumar","Dubey, Vikash Kumar","32362243"],"abstract":["The 2019-novel coronavirus (nCoV) has caused a global health crisis by causing coronavirus disease-19 (COVID-19) pandemic in the human population. The unavailability of specific vaccines and anti-viral drug for nCoV, science demands sincere efforts in the field of drug design and discovery for COVID-19. The novel coronavirus main protease (SARS-CoV-2 Mpro) play a crucial role during the disease propagation, and hence SARS-CoV-2 Mpro represents as a drug target for the drug discovery. Herein, we have applied bioinformatics approach for screening of chemical compounds from Indian spices as potent inhibitors of SARS-CoV-2 main protease (PDBID: 6Y84). The structure files of Indian spices chemical compounds were taken from PubChem database or Zinc database and screened by molecular docking, by using AutoDock-4.2, MGLTools-1.5.6, Raccoon virtual screening tools. Top 04 hits based on their highest binding affinity were analyzed. Carnosol exhibited highest binding affinity -8.2 Kcal/mol and strong and stable interactions with the amino acid residues present on the active site of SARS-CoV-2 Mpro. Arjunglucoside-I (-7.88 Kcal/mol) and Rosmanol (-7.99 Kcal/mol) also showed a strong and stable binding affinity with favourable ADME properties. These compounds on MD simulations for 50ns shows strong hydrogen-bonding interactions with the protein active site and remains stable inside the active site. Our virtual screening results suggest that these small chemical molecules can be used as potential inhibitors against SARS-CoV-2 Mpro and may have an anti-viral effect on nCoV. However, further validation and investigation of these inhibitors against SARS-CoV-2 main protease are needed to claim their candidacy for clinical trials."],"journal":"J Biomol Struct Dyn","authors":["Umesh","Kundu, Debanjan","Selvaraj, Chandrabose","Singh, Sanjeev Kumar","Dubey, Vikash Kumar"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362243","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1763202","keywords":["adme","bioinformatics","corona virus disease-2019 (covid-19","molecular docking","novel coronavirus (ncov)","novel coronavirus main protease (sars-cov-2 mpro)"],"locations":["Indian","Indian","Raccoon","Indian"],"countries":["India"],"countries_codes":["IND|India"],"e_drugs":["sericoside","carnosol","rosmanol"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495987482624,"score":243.43306}]}